Cerchietti Research Lab

Publications

Found 86 results
Filters: First Letter Of Last Name is S  [Clear All Filters]
2019
Li M, Chiang Y-L, Lyssiotis CA, Teater MR, Hong JYoung, Shen H, Wang L, Hu J, Jing H, Chen Z et al..  2019.  Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis.. Cancer Cell. 35(6):916-931.e9.
2018
Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2018.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.. Leuk Lymphoma. 59(1):256-258.
Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al..  2018.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.
Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al..  2018.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.
Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al..  2018.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.
Ruan J, Martin P, Christos P, Cerchietti L, Tam W, Shah B, Schuster SJ, Rodriguez A, Hyman D, Calvo-Vidal MNieves et al..  2018.  Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma.. Blood. 132(19):2016-2025.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.
Wei X, M Calvo-Vidal N, Chen S, Wu G, Revuelta MV, Sun J, Zhang J, Walsh MF, Nichols KE, Joseph V et al..  2018.  Germline mutations in lysine specific demethylase 1 (LSD1/KDM1A) confer susceptibility to multiple myeloma.. Cancer Res.
2017
Rutherford SC, Stewart EN, Chen Z, Chadburn A, Wehrli NE, van Besien K, Martin P, Furman RR, Leonard JP, Cerchietti L.  2017.  The eIF4E inhibitor ribavirin as a potential antilymphoma therapeutic: early clinical data.. Leuk Lymphoma. :1-3.
Apoorva F, Tian YF, Pierpont TM, Bassen DM, Cerchietti L, Butcher JT, Weiss RS, Singh A.  2017.  Lymph Node Stiffness Mimicking Hydrogels Regulate Human B Cell Lymphoma Growth and Cell Surface Receptor Expression in a Molecular Subtype-Specific Manner.. J Biomed Mater Res A.
2016
Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.
Rodina A, Wang T, Yan P, Gomes EDaGama, Dunphy MPS, Pillarsetty N, Koren J, Gerecitano JF, Taldone T, Zong H et al..  2016.  The epichaperome is an integrated chaperome network that facilitates tumour survival.. Nature. 538(7625):397-401.
Cardenas MG, Yu W, Beguelin W, Teater MR, Geng H, Goldstein RL, Oswald E, Hatzi K, Yang S-N, Cohen J et al..  2016.  Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma.. J Clin Invest.
2015
Pan H, Jiang Y, Boi M, Tabbò F, Redmond D, Nie K, Ladetto M, Chiappella A, Cerchietti L, Shaknovich R et al..  2015.  Epigenomic evolution in diffuse large B-cell lymphomas.. Nat Commun. 6:6921.
Purwada A, Jaiswal MK, Ahn H, Nojima T, Kitamura D, Gaharwar AK, Cerchietti L, Singh A.  2015.  Ex vivo engineered immune organoids for controlled germinal center reactions.. Biomaterials. 63:24-34.
Tian YF, Ahn H, Schneider RS, Yang SNing, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A.  2015.  Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.. Biomaterials. 73:110-9.
Tian YF, Ahn H, Schneider RS, Yang SNing, Roman-Gonzalez L, Melnick AM, Cerchietti L, Singh A.  2015.  Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells.. Biomaterials. 73:110-9.
Abate F, Todaro M, van der Krogt J-A, Boi M, Landra I, Machiorlatti R, Tabbò F, Messana K, Abele C, Barreca A et al..  2015.  A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation.. Leukemia. 29(6):1390-401.
Goldstein RL, Yang SNing, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G et al..  2015.  Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.. J Clin Invest. 125(12):4559-71.
2014
Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, Gomes EMDaGama, Yang C, Patel MR, Shrestha L et al..  2014.  Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer.. ACS Chem Biol. 9(8):1698-705.
Rodina A, Taldone T, Kang Y, Patel PD, Koren J, Yan P, Gomes EMDaGama, Yang C, Patel MR, Shrestha L et al..  2014.  Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer.. ACS Chem Biol. 9(8):1698-705.
Ha K, Fiskus W, Choi DSoon, Bhaskara S, Cerchietti L, Devaraj SGT, Shah B, Sharma S, Chang JC, Melnick AM et al..  2014.  Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.. Oncotarget. 5(14):5637-50.
Ha K, Fiskus W, Choi DSoon, Bhaskara S, Cerchietti L, Devaraj SGT, Shah B, Sharma S, Chang JC, Melnick AM et al..  2014.  Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.. Oncotarget. 5(14):5637-50.